Atlas Private Wealth Management raised its stake in Johnson & Johnson (NYSE:JNJ – Get Rating) by 6.5% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 20,200 shares of the company’s stock after purchasing an additional 1,234 shares during the quarter. Johnson & Johnson makes up about 1.6% of Atlas Private Wealth Management’s portfolio, making the stock its 9th biggest holding. Atlas Private Wealth Management’s holdings in Johnson & Johnson were worth $3,568,000 as of its most recent filing with the Securities & Exchange Commission.
A number of other institutional investors and hedge funds also recently made changes to their positions in JNJ. Veracity Capital LLC raised its position in Johnson & Johnson by 1.2% during the fourth quarter. Veracity Capital LLC now owns 5,027 shares of the company’s stock valued at $888,000 after purchasing an additional 59 shares in the last quarter. Sandy Cove Advisors LLC raised its holdings in shares of Johnson & Johnson by 1.6% during the 3rd quarter. Sandy Cove Advisors LLC now owns 3,703 shares of the company’s stock worth $605,000 after buying an additional 60 shares in the last quarter. Paces Ferry Wealth Advisors LLC lifted its position in shares of Johnson & Johnson by 0.7% during the 3rd quarter. Paces Ferry Wealth Advisors LLC now owns 8,724 shares of the company’s stock worth $1,425,000 after buying an additional 62 shares during the last quarter. Mason & Associates Inc boosted its stake in Johnson & Johnson by 4.9% in the third quarter. Mason & Associates Inc now owns 1,317 shares of the company’s stock valued at $215,000 after buying an additional 62 shares in the last quarter. Finally, Magnolia Capital Advisors LLC raised its stake in Johnson & Johnson by 0.7% during the third quarter. Magnolia Capital Advisors LLC now owns 8,883 shares of the company’s stock worth $1,451,000 after acquiring an additional 62 shares in the last quarter. Institutional investors own 67.94% of the company’s stock.
Wall Street Analyst Weigh In
Several brokerages recently issued reports on JNJ. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $215.00 price target on shares of Johnson & Johnson in a report on Wednesday, February 1st. SVB Leerink decreased their price objective on Johnson & Johnson from $194.00 to $186.00 and set an “outperform” rating for the company in a report on Friday, January 20th. Atlantic Securities boosted their price target on shares of Johnson & Johnson from $160.00 to $168.00 and gave the company a “neutral” rating in a research note on Wednesday, January 25th. StockNews.com began coverage on shares of Johnson & Johnson in a report on Thursday, March 16th. They set a “strong-buy” rating for the company. Finally, Guggenheim began coverage on shares of Johnson & Johnson in a research report on Tuesday, February 28th. They issued a “neutral” rating and a $161.00 price target on the stock. Seven research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, Johnson & Johnson presently has a consensus rating of “Moderate Buy” and a consensus target price of $174.73.
Insider Activity at Johnson & Johnson
Johnson & Johnson Stock Performance
Shares of JNJ stock opened at $153.30 on Tuesday. Johnson & Johnson has a 52 week low of $150.11 and a 52 week high of $186.69. The firm’s 50-day simple moving average is $159.35 and its two-hundred day simple moving average is $167.49. The firm has a market cap of $399.24 billion, a price-to-earnings ratio of 22.74, a P/E/G ratio of 2.63 and a beta of 0.54. The company has a debt-to-equity ratio of 0.35, a quick ratio of 0.77 and a current ratio of 0.99.
Johnson & Johnson (NYSE:JNJ – Get Rating) last posted its quarterly earnings results on Tuesday, January 24th. The company reported $2.35 EPS for the quarter, topping analysts’ consensus estimates of $2.22 by $0.13. Johnson & Johnson had a net margin of 18.90% and a return on equity of 35.76%. The company had revenue of $23.71 billion for the quarter, compared to analysts’ expectations of $23.90 billion. During the same quarter in the previous year, the firm posted $2.13 EPS. Johnson & Johnson’s revenue was down 4.4% on a year-over-year basis. As a group, equities analysts forecast that Johnson & Johnson will post 10.5 earnings per share for the current year.
Johnson & Johnson Dividend Announcement
The company also recently disclosed a quarterly dividend, which was paid on Tuesday, March 7th. Investors of record on Tuesday, February 21st were issued a $1.13 dividend. This represents a $4.52 annualized dividend and a yield of 2.95%. The ex-dividend date of this dividend was Friday, February 17th. Johnson & Johnson’s dividend payout ratio (DPR) is currently 67.06%.
Johnson & Johnson Profile
Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and MedTech. The Consumer Health segment includes products focused on personal healthcare used in the Skin Health/Beauty, Over-the-Counter medicines, Baby Care, Oral Care, Women’s Health and Wound Care markets.
Featured Stories
- Get a free copy of the StockNews.com research report on Johnson & Johnson (JNJ)
- 3 High Yields On Breakout Watch With Analyst Tailwinds
- Sanofi, Regeneron Shares Pop On Big News About COPD Treatment
- 3 Financials The Insiders Are Buying
- Can Carnival Cruise Lines Set Sail For New Highs?
- If Safety is Your Concern, Then Take a Look at Sandy Spring Bank
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.
